Abstract
Purpose: Osteoarthritis (OA) is a painful and disabling disease involving the degeneration of diarthrodial joints, with a hallmark feature of cartilage loss. Currently, there are no approved treatments that can protect or regenerate damaged cartilage. Our lab has investigated activation of the parathyroid hormone receptor type 1 (PTH1R), which is expressed by articular chondrocytes in the setting of OA, with abaloparatide (ABL), a bone anabolic agent FDA-approved for treatment of osteoporosis for postmenopausal women with increased fracture risk.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
